Israeli drug companies Clal Biotech Industries and BiolineRX sign an agreement for developing and commercializing Clal’s BL-8040, a drug designed for treating acute leukemia and other types of blood cancer. The American FDA has approved the companies’ investigational new drug application.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments